Genelux Corporation
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $132.7M
- Price
- $2.96
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.36%
- Volume
- 179.5K
Quote data as of 7:05 AM ET
About
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Quick stats
Shares outstanding44.8M
Computed float38.2M
Float sourceUnknown
Cash runway (months)9.2
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001231457
Websitehttps://www.genelux.com
AI Summary
AI-generated9d agominorbullishclinical trialGenelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
Genelux announced the publication of translational data from the Phase 1b/2 VIRO-15 trial in Gynecologic Oncology Reports, validating the mechanism of action for Olvi-Vec in platinum-resistant ovarian cancer.
The analysis demonstrated that Olvi-Vec modulates the tumor microenvironment, activates immune pathways, and induces gene expression changes consistent with chemotherapy sensitization.
These findings provide biological support for the ongoing registrational Phase 3 OnPrime/GOG-3076 study and reinforce the rationale for systemic use in lung cancer indications.